ASEAN Ministers Warn Middle East Conflict Threatens Regional Stability and Energy Security 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
SpaceX Targets Thursday Launch for Starship's 13th Test Flight After Last-Minute Delay 
Pakistan Seeks $10 Billion U.S. Exchange Stabilization Fund to Boost Forex Reserves 
Asian Currencies Hold Steady as Middle East Tensions Boost US Dollar, Oil Concerns 
TSMC Sees Multi-Year AI Chip Demand as Arizona Expansion Reaches $265 Billion 
Houthi Naval Blockade on Saudi Arabia Escalates Iran Conflict, Threatens Global Oil Supply 
US Stock Exchanges Face Earnings Test as Trading Boom Meets Crypto Competition 
Germany Producer Prices Rise 1.8% in June, Missing Forecasts 
Japan PM Sanae Takaichi Unveils Growth Plan as BOJ Independence Concerns Lift Bond Yields 
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates 
Why Maruti Suzuki Is Losing Market Share in India as SUVs and Premium Features Gain Popularity 
US Stock Futures Steady Ahead of Tesla, Alphabet Earnings as Iran Conflict Keeps Markets on Edge 
Foxconn Wins First SpaceX AI Server Contract Worth Estimated $52 Billion 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
KPMG Australia Appoints John Sams as CEO Following Audit Leak Scandal 
Hong Kong AI Stocks Rally as Moonshot AI’s Kimi K3 Launch Boosts Market Optimism 
Cresco Labs Inc. and Columbia Care are cannabis and medical marijuana companies that have previously announced their merger through an acquisition deal. In March 2022, they agreed to a transaction that would have created the largest cannabis operator in the United States, but the agreement seems to have gone up in smoke.
Cresco Labs and Columbia made a new announcement on Monday, July 31, stating they have terminated their $2 billion merger deal. This development comes as the industry is waiting for banking reforms, as per CNBC.
Moreover, it was suggested that the contract has been called off as the cannabis industry has been showing indications of a slowdown as it also deals with various economic issues and challenges with regulators. The cannabis companies mutually agreed to scrap their agreement, so there will be no penalties or fees to pay for both parties.
Another reason for the failure of the merger is the fact that Cresco Labs and Columbia Care were not able to unload enough assets required to secure the regulators' seal of approval. They were given the June 30 deadline for this but failed to comply.
"In light of the evolving landscape in the cannabis industry, we believe the decision to terminate the planned transaction is in the long-term interest of Cresco Labs and our shareholders," Cresco Labs' co-founder and chief executive officer, Charles Bachtell, said in a press release.
"We want to express our sincere gratitude to Columbia Care for their valuable collaboration and dedication during this transaction. While this is not the outcome we originally hoped for, we are confident Cresco Labs is in a stronger position moving forward."
Columbia Care's co-founder and CEO, Nicholas Vita, added, "After careful consideration, we are confident in the mutual decision to move forward as separate, standalone companies. This is the best path forward for Columbia Care's employees, customers, and shareholders. We are thankful for the collaboration and partnership with the Cresco team throughout this extensive process."
Photo by: Kimzy Nanney/Unsplash
